The global Norovirus Diagnostics Market is set to witness substantial growth, with the market projected to surge at a Compound Annual Growth Rate (CAGR) of 8.7% between 2024 and 2031, reaching an estimated valuation of US$ 130.0 Mn by the end of the forecast period. In 2024, the market stood at a value of US$ 70 Mn, reflecting its current upward trajectory.
The proliferation of diagnostics laboratories is also contributing to the market's growth, bringing about favorable effects on sales and revenue for manufacturers. As these diagnostics labs continue to emerge, the market for norovirus diagnostics is set to benefit significantly.
The underdiagnosis of norovirus is another issue impacting patient health, as individuals may not seek medical attention due to the stigma associated with the disease or a lack of understanding about its symptoms. The symptoms of norovirus infection, including cramps, nausea, vomiting, diarrhea, and low-grade fever, can be easily confused with other illnesses, leading to misdiagnosis or neglect. To address these challenges, efforts are needed to raise awareness and educate the public about norovirus and its diagnostic options.
This product will be delivered within 1-3 business days.
Rising Incidence of Norovirus Disease
One of the key driving factors behind this remarkable growth is the escalating incidence of norovirus disease. Leading participants and manufacturers in the field are adopting sophisticated techniques to combat this highly contagious stomach and intestinal virus. As a result, medical device companies have increased their Research and Development (R&D) investments to develop advanced diagnostic tools that are more sensitive and efficient. This commitment to innovation is expected to fuel the expansion of the Norovirus Diagnostics Market in the near future.The proliferation of diagnostics laboratories is also contributing to the market's growth, bringing about favorable effects on sales and revenue for manufacturers. As these diagnostics labs continue to emerge, the market for norovirus diagnostics is set to benefit significantly.
Lack of Awareness about Norovirus
However, despite the promising growth prospects, there are certain impediments affecting the Norovirus Diagnostics Market. Factors such as the prevalence of norovirus infection in low-income nations and the lack of awareness about the symptoms preceding norovirus infection have hindered the market's expansion.The underdiagnosis of norovirus is another issue impacting patient health, as individuals may not seek medical attention due to the stigma associated with the disease or a lack of understanding about its symptoms. The symptoms of norovirus infection, including cramps, nausea, vomiting, diarrhea, and low-grade fever, can be easily confused with other illnesses, leading to misdiagnosis or neglect. To address these challenges, efforts are needed to raise awareness and educate the public about norovirus and its diagnostic options.
Booming U.S. Market
The United States holds a significant share of the Norovirus Diagnostics Market due to the high prevalence of norovirus infections in the country. The presence of major companies and increased R&D investments have contributed to the growth of this market. Additionally, government initiatives aimed at strengthening healthcare systems and regulatory capacities are expected to further propel market expansion.Lucrative Prospects in Germany's Medical Wellness Market
In Germany, the medical wellness market is thriving, primarily driven by the country's strong emphasis on fitness and well-being. Major players in the industry are collaborating to develop new products, enhancing the market's growth potential.China Emerges as a Prominent Market for Medical Wellness
China is becoming a prominent market for medical wellness, with manufacturers focusing on expanding their global presence, expertise, and technological capabilities. This strategic approach is making norovirus diagnostics products more widely accessible in the Chinese market.Competitive Landscape Analysis
The introduction and approval of innovative products are central elements of these manufacturers' strategies to enhance their market presence.Key Companies Profiled:
- Abbott
- R-Biopharm AG
- ELITechGroup AG
- Danaher Corporation (Cepheid)
- Meridian Bioscience Inc.
- Eiken Chemical Co.
- Altona Diagnostics GmbH
- CerTest Biotec S.L
- Elisabeth Pharmacon, Spol. S Ro
- Qiagen
- Altona Diagnostics GmbH
- Eiken Chemical Co
Key Segments Covered in Norovirus Diagnostics Industry Research
By Product
- Rapid Test Kits
- PCR Kits
- ELISA based kits
By End-User
- Hospitals
- Diagnostics Labs
- Clinics
Region
- North America
- Latin America
- Europe
- South Asia
- East Asia
- Oceania
- Middle East & Africa
This product will be delivered within 1-3 business days.
Table of Contents
1. Executive Summary
2. Market Overview
3. Global Norovirus Diagnostics Market Outlook, 2018 - 2031
4. North America Norovirus Diagnostics Market Outlook, 2018 - 2031
5. Europe Norovirus Diagnostics Market Outlook, 2018 - 2031
6. Asia Pacific Norovirus Diagnostics Market Outlook, 2018 - 2031
7. Latin America Norovirus Diagnostics Market Outlook, 2018 - 2031
8. Middle East & Africa Norovirus Diagnostics Market Outlook, 2018 - 2031
9. Competitive Landscape
10. Appendix
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Abbott
- R-Biopharm AG
- Cepheid
- Luminex Corporation
- Meridian Bioscience
- ELITechGroup
- Biomérieux SA
- CerTest Biotec S.L.
- Elisabeth Pharmacon, Spol. S Ro
- Qiagen
- Altona Diagnostics GmbH
- Eiken Chemical Co
Methodology
LOADING...
